Gastroenterological endpoints in drug trials for cystic fibrosis

Frank A. J. A. Bodewes*, Henkjan J. Verkade, Micheal Wilschanski

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)

Abstract

The phenotype of cystic fibrosis includes a wide variety of clinical and biochemical gastrointestinal presentations. These gastrointestinal characteristics of the disease have come under renewed interest as potential outcome measures and clinical endpoints for therapeutic trials in cystic fibrosis. Established gastrointestinal clinical endpoints, like e.g. fecal elastase-1, are already used in trials. Other potential gastrointestinal outcome measures gather more scientific interest for evaluation in future trials. Gastrointestinal outcome measures look particularly relevant and promising for trials in CF patients with normal lung function or therapeutic studies in young children and infants. We review, the currently reported gastrointestinal effects of CFTR modulation therapies and discuss the potential of gastrointestinal outcome measures for therapeutic trials in cystic fibrosis. Pediatr Pulmonol. 2016;51:S18-S22. (c) 2016 Wiley Periodicals, Inc.

Original languageEnglish
Pages (from-to)S18-S22
Number of pages5
JournalPediatric Pulmonology
Volume51
DOIs
Publication statusPublished - Oct-2016

Keywords

  • cystic fibrosis
  • gastrointestinal
  • clinical outcome measures
  • clinical endpoint
  • biomarkers
  • INFLAMMATORY-BOWEL-DISEASE
  • G551D MUTATION
  • INTESTINAL INFLAMMATION
  • CFTR MODULATORS
  • IVACAFTOR
  • EXPRESSION
  • BIOMARKERS
  • ORGANOIDS
  • CAPSULE
  • TRANSIT

Cite this